Not checkedNot checked for notices yet.
Tafenoquine for the prevention of Plasmodium vivax malaria relapse
James A Watson, Narimane Nekkab, Michael White
The Lancet Microbe · 2021
doi:10.1016/s2666-5247(21)00062-8 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Tafenoquine (Krintafel) is the first new drug to be approved for the treatment of relapsing Plasmodium vivax malaria in 70 years. Tafenoquine was engineered to be a metabolically stable and thus slowly eliminated version of the 8-aminoquinoline, primaquine, providing relapse prevention with a single dose as compared to 1–2 weeks of daily primaquine. Although it also causes protracted haemolysis in individuals with glucose-6-phosphate dehydrogenase deficiency, it has the potential to accelerate P vivax elimination.
Abstract licence: CC BY-NC
References3
3 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.